Disease progression and costs at the 3‐year follow‐up of the GERAS‐US study

Disease progression and costs at the 3‐year follow‐up of the GERAS‐US study

Abstract Introduction GERAS‐US prospectively characterized clinical and economic outcomes of early symptomatic Alzheimer's disease (AD). Societal cost changes were examined in amyloid‐positive patients with mild cognitive impairment due to AD (MCI) and mild dementia due to AD (MILD). Methods Co...

Full description

Bibliographic Details
Main Authors: Julie M. Chandler, Dorene M. Rentz, Anthony Zagar, Yongin Kim, Ronald L. Schwartz, Howard Fillit
Format: Article
Language:English
Published: Wiley 2023-04-01
Series:Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Subjects:
amyloid
dementia
mild cognitive impairment
societal burden
Online Access:https://doi.org/10.1002/dad2.12430

Similar Items

Similar Items